Table 5_KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell

A meta-analysis of 798 patients from two phase 3 randomized controlled trials evaluates KRASG12C inhibitors for non-small cell lung cancer. Shuang Liang authored this pooled analysis, which was last updated on 2026-04-15. The 63.5 KB document reports hazard ratios for progression-free survival and central nervous system progression-free survival, along with objective response rates and treatment-related adverse events.

Use Cases

• Compare progression-free survival (PFS) outcomes between targeted therapy and chemotherapy based on reported hazard ratios.
• Analyze central nervous system (CNS) efficacy of KRASG12C inhibitors based on CNS-PFS data.
• Evaluate treatment response rates based on objective response rate (ORR) and disease control rate (DCR) metrics.
• Assess the safety profile of KRASG12C inhibitors based on reported treatment-related adverse events (TRAEs) and grade 3–5 event rates.

Strengths

• Data is derived from two phase 3 randomized controlled trials (CodeBreaK 200 and KRYSTAL-12), a high-evidence study design.
• Analysis includes 798 patients, providing a substantial sample size for the pooled results.
• Reports specific statistical outcomes, including hazard ratios for PFS (HR: 0.62) and CNS-PFS (HR: 0.55), with confidence intervals and p-values.
• Includes detailed safety data, listing the top three grade 3–5 treatment-related adverse events with specific incidence percentages (e.g., diarrhea at 7.63%).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (63.5 KB), indicating it contains summary results rather than individual patient-level data.

Provenance

Source

figshare, author Shuang Liang.

Collection Method

Comprehensive literature search across six databases and meta-analysis of identified phase 3 RCTs.

Freshness

Last updated 2026-04-15 05:47:42; freshness should be verified.